Earnings analysis of drugmakers' quarterly results, in-depth business analysis and the CompePharma View, ten new pieces every day.
With $5.8M in cash and about $0.7M in royalty revenue, Xenetic is pairing a Q1 2027 all-stock acquisition with a first DNase I CAR-T dosing, as peers fund through royalty sales, licences and divestments.
With $288M in cash and a runway into 2028, MacroGenics is using non-dilutive deals to bet on B7-H3 ADC MGC026, starting in head and neck cancer.
The UK regulator's Phase 1 finding is confined to one product market, and the parties plan to reuse the EC-agreed divestment. Pharma dealmakers can learn from that.
Theriva's divestment of its antibiotic-enzyme assets to Biossil Labs is small in dollars but fits a day of triage, licensing and consolidation among cash-constrained developers.
Silence reported positive Phase 2 polycythemia vera data and $247.7M in cash while its sale to Merck KGaA is pending, a sharp contrast with the weaker end of biotech's deal market.
After laromestrocel failed its primary endpoint in infant HLHS, Longeveron is seeking FDA input and weighing a sale or merger, a stark contrast with this week's better-funded deals.
Kiora has taken ex-Asia rights to Senju's oral calpain inhibitor for retinal artery occlusion, an early-stage option that sits alongside a busy week of eye-care and licensing deals.
Ocugen has out-licensed OCU400 for Australia, NZ and ASEAN before its Q1 2027 Phase 3 readout, part of a week of deals that put regional rights, portfolios and capacity on the table.
Perspective Therapeutics pairs FDA Fast Track for PSV359 with a Merck Keytruda agreement, while a busy deal week shows buyers paying for assets, capacity and regional rights.
A Japan-only licence for anti-TLR4 antibody paridiprubart is worth over $140m on paper, but this week's other deals show where capital is actually being committed.
The oncology biotech has paid undisclosed cash for Aqilion's ACR-525 and a preclinical PKCθ programme, owing no milestones or royalties, a structure that shifts all future risk onto Acrivon.
A SPAC merger valuing cannabinoid API supplier Brains Bioceutical at about $750 million pre-money shows how public-market access is being traded for scale, set against a week of niche, capital-sensitive deals.